Yuviwel
@yuviwel.com
YUVIWEL can help make the difference.
Yuviwel's Company Logos
Yuviwel's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#FFB86E
Macaroni and Cheese
255, 184, 110
31, 100, 72
0, 28, 57, 0
#0B2E5A
Downriver
11, 46, 90
213, 78, 20
88, 49, 0, 65
#FD6D6A
Bittersweet
253, 109, 106
1, 97, 70
0, 57, 58, 1
About Yuviwel
YUVIWEL® (navepegritide) is a once-weekly, FDA-approved prescription medicine developed by Ascendis Pharma Endocrinology, Inc., indicated to increase linear growth in children aged 2 years and older with achondroplasia — the most common form of short-limbed dwarfism — whose growth plates are still open. The first and only once-weekly treatment approved for this condition, YUVIWEL offers families 313 injection-free days per year and can be administered at any time of day, fitting flexibly into family routines. Approved under accelerated approval based on improved annualized growth velocity in clinical trials, the product is supported by Ascendis's A•S•A•P (Ascendis Signature Access Program) patient support service, including dedicated Patient Access Liaisons
